FDA approves Corcept's Lifyorli for ovarian cancer months early
FDA approves Corcept's Lifyorli for ovarian cancer months early
Body unavailable. Use the original source.
FDA approves Corcept's Lifyorli for ovarian cancer months early
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.